ONCOSEC MEDICAL INC | 0,20 Euro | 0,00 0 % | |
| WKN: A1H89N ISIN: US68234L1089 Ticker-Symbol: ONM | Berlin | 24.05.13 | 08:08 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 21.05. | ONCOSEC MEDICAL Inc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | |
| 18.04. | ONCOSEC MEDICAL Inc - 8-K, Submission of Matters to a Vote of Security Holders | - | SEC Filings | |
| 25.03. | OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients | 52 | PR Newswire | |
| SAN DIEGO, March 25, 2013 /PRNewswire/ --OncoSec Medical Inc. (OTCQB: ONCS) - a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors... Mehr lesen zu: OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients | ||||
| 18.03. | OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York | 54 | PR Newswire | |
| SAN DIEGO, March 18, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor... Mehr lesen zu: OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York | ||||
| 14.03. | OncoSec Medical to Present at the 25th Annual Roth Conference | 56 | PR Newswire | |
| SAN DIEGO, March 14, 2013 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical to Present at the 25th Annual Roth Conference | ||||
| 26.02. | OncoSec Medical Announces Formation of Melanoma Advisory Board | 49 | PR Newswire | |
| SAN DIEGO, Feb. 26, 2013 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical Announces Formation of Melanoma Advisory Board | ||||
| 19.02. | OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer | 60 | PR Newswire | |
| SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer | ||||
| 06.02. | OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference | 36 | PR Newswire | |
| SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference | ||||
| 17.01. | OncoSec Medical to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22 | 50 | PR Newswire | |
| SAN DIEGO, Jan. 17, 2013 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22 | ||||
| 15.01. | OncoSec Medical Announces 2013 Milestones and Corporate Strategy | 53 | PR Newswire | |
| SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical Announces 2013 Milestones and Corporate Strategy | ||||
| 03.01. | OncoSec Medical to Present at Biotech Showcase(TM) 2013 in San Francisco on January 8 | 52 | PR Newswire | |
| SAN DIEGO, Jan. 3, 2013 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical to Present at Biotech Showcase(TM) 2013 in San Francisco on January 8 | ||||
| 02.01. | marketexclusive: Marketexclusive.com: OncoSec offers great opportunities but investors are wary | 75 | Thomson Reuters ONE | |
| OncoSec offers great opportunities but investors are wary Direct Link: http://marketexclusive.com/news/details/4500-OncoSec-offers-great-opportunities-but-investors-are-wary (http://marketexclusive.com/news/details/4500-OncoSec-offers-great-opportunities-but-investors-are-wary)... Mehr lesen zu: marketexclusive: Marketexclusive.com: OncoSec offers great opportunities but investors are wary | ||||
| 17.12. | OncoSec Looking For A Rich Uncle | 4 | Seeking Alpha | |
| 13.12. | OncoSec Medical Announces $7.2 Million Public Offering | 61 | PR Newswire | |
| SAN DIEGO, Dec. 13, 2012 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid... Mehr lesen zu: OncoSec Medical Announces $7.2 Million Public Offering | ||||
| 06.12. | OncoSec Medical: 2013 Will Be A Year Of Crucial Events | 4 | Seeking Alpha | |
| 04.12. | OncoSec Medical to Present Data at DNA Vaccines 2012 Conference | 69 | PR Newswire | |
| SAN DIEGO, Dec. 04, 2012 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat... Mehr lesen zu: OncoSec Medical to Present Data at DNA Vaccines 2012 Conference | ||||
| 27.11. | OncoSec Medical to Present at NYSSA Life Sciences and LD Micro Investor Conferences | 74 | PR Newswire | |
| SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers... Mehr lesen zu: OncoSec Medical to Present at NYSSA Life Sciences and LD Micro Investor Conferences | ||||
| 15.11. | OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients | 74 | PR Newswire | |
| SAN DIEGO, Nov. 15, 2012 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors,... Mehr lesen zu: OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients | ||||
| 14.11. | OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients | 83 | PR Newswire | |
| SAN DIEGO, Nov. 14, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors... Mehr lesen zu: OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients | ||||
| 23.10. | OncoSec Medical Incorporated Reports Positive Preliminary Efficacy and Safety Results from Phase II Study of ImmunoPulse in Merkel Cell Carcinoma Patients | 67 | PR Newswire | |
| SAN DIEGO, Oct. 23, 2012 /PRNewswire/ --OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor... Mehr lesen zu: OncoSec Medical Incorporated Reports Positive Preliminary Efficacy and Safety Results from Phase II Study of ImmunoPulse in Merkel Cell Carcinoma Patients | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CALYX BIO-VENTURES | 0,193 | 0 % | Calyx Announces Commercial Launch of Higher Yielding Variety of Resonance(R) Carinata |
| BIONOMICS | 0,248 | -3,50 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.03.2013 - 1 |
| ALCHEMIA | 0,229 | -6,15 % | Alchemia Limited Provides Company Update |
| AFFYMAX | 1,061 | +0,28 % | Affymax Inc is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com |
| BIOTIE THERAPIES | 0,338 | -3,98 % | Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence |
